ConductScience.org, home

Paper33740902

Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial.

Kudrow D and 6 others. BMC Neurol, 2021. Cited by 69 papers, by iCite.

Cite this record

ConductScience Library. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. Papers, record 33740902. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33740902

Download JSON
Disease
migraine disorder166 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial.
PubMed
Journal
BMC Neurol
PubMed
Year
2021
PubMed
Publication types
Clinical Trial, Phase III, Journal Article
PubMed
Citations, by iCite
69
iCite
Relative citation ratio, by iCite
5.88
iCite
Revised in PubMed
2021-05-31
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kudrow DDavid
2Cady RKRoger K
3Allan BBrent
4Pederson SMSusan M
5Hirman JJoe
6Mehta LRLahar R
7Schaeffler BABarbara A

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, Monoclonal, HumanizedMajor topic
Calcitonin Gene-Related PeptideMajor topic
Migraine DisordersMajor topic
Administration, Intravenous
Adult
Female
Humans
Male
Middle Aged
Nasopharyngitis
Patient Reported Outcome Measures
Quality of Life
Treatment Outcome

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02985398An Open Label Trial of ALD403 (Eptinezumab) in Chronic MigraineDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References30

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129368949Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.Cephalalgia2018https://conductscience.org/library/papers/29368949PubMed
230661365CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.Cephalalgia2019https://conductscience.org/library/papers/30661365PubMed
328984356A Real-World Analysis of Migraine: A Cross-Sectional Study of Disease Burden and Treatment Patterns.Headache2017https://conductscience.org/library/papers/28984356PubMed
425304766The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results.Cephalalgia2015https://conductscience.org/library/papers/25304766PubMed
530446596Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.Neurology2018https://conductscience.org/library/papers/30446596PubMed
614651415A six-item short-form survey for measuring headache impact: the HIT-6.Qual Life Res2003https://conductscience.org/library/papers/14651415PubMed
728409893Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.Clin Pharmacol Drug Dev2017https://conductscience.org/library/papers/28409893PubMed
823458496Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II).Headache2013https://conductscience.org/library/papers/23458496PubMed
932366601Pharmacologic Characterization of ALD403, a Potent Neutralizing Humanized Monoclonal Antibody Against the Calcitonin Gene-Related Peptide.J Pharmacol Exp Ther2020https://conductscience.org/library/papers/32366601PubMed
1029697154A Phase-by-Phase Review of Migraine Pathophysiology.Headache2018https://conductscience.org/library/papers/29697154PubMed
1120819842Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine.Cephalalgia2011https://conductscience.org/library/papers/20819842PubMed
1221762134Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS).Headache2011https://conductscience.org/library/papers/21762134PubMed
1329691490CGRP as the target of new migraine therapies - successful translation from bench to clinic.Nat Rev Neurol2018https://conductscience.org/library/papers/29691490PubMed
1428919117
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
Lancet2017https://conductscience.org/library/papers/28919117PubMed
1532075406Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1).Cephalalgia2020https://conductscience.org/library/papers/32075406PubMed
1625297013
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.
Lancet Neurol2014https://conductscience.org/library/papers/25297013PubMed
1730536394The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice.Headache2019https://conductscience.org/library/papers/30536394PubMed
1829171818Fremanezumab for the Preventive Treatment of Chronic Migraine.N Engl J Med2017https://conductscience.org/library/papers/29171818PubMed
1932209650Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.Neurology2020https://conductscience.org/library/papers/32209650PubMed
2029504482Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.Cephalalgia2018https://conductscience.org/library/papers/29504482PubMed

See all 30 referencesDownload CSV of references

Cited by45

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.

PMIDTitleJournalYearIn PapersSource
42348309ESTELA-Study: Long-Term Effectiveness and Safety of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Real-World Clinical Practice.Brain Behav2026https://conductscience.org/library/papers/42348309PubMed
42201619CGRP-targeted therapies for migraine and the risk of infection.Intern Emerg Med2026https://conductscience.org/library/papers/42201619PubMed
41996064Long-Term Reductions in Headache Frequency, Severity, and Disability with Eptinezumab in Adults with Chronic Migraine: Results from the PREVAIL Trial.Pain Ther2026https://conductscience.org/library/papers/41996064PubMed
41484941Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review.J Headache Pain2026https://conductscience.org/library/papers/41484941PubMed
41383230SAFE-CGRP study: multicenter retrospective evaluation of the safety of CGRP pathway-targeting monoclonal antibodies in migraine with relevant comorbidities or conditions excluded from trials.Front Neurol2025https://conductscience.org/library/papers/41383230PubMed
41275111Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: results of the 60-week open-label SUNSET trial.J Headache Pain2025https://conductscience.org/library/papers/41275111PubMed
40838472Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo-Controlled Study.Eur J Neurol2025https://conductscience.org/library/papers/40838472PubMed
40628864Comprehensive safety analysis of adverse events associated with eptinezumab in migraine treatment.Sci Rep2025https://conductscience.org/library/papers/40628864PubMed
40444655Pharmacokinetics and safety of eptinezumab in children and adolescents with migraine.Headache2025https://conductscience.org/library/papers/40444655PubMed
40329208Unmasking the relationship between CGRP and glutamate: from peripheral excitation to central sensitization in migraine.J Headache Pain2025https://conductscience.org/library/papers/40329208PubMed
40033803Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database-based observational cohort study.Headache2025https://conductscience.org/library/papers/40033803PubMed
39501727Long-term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial.Headache2025https://conductscience.org/library/papers/39501727PubMed
38938785Revolutionizing migraine management: advances and challenges in CGRP-targeted therapies and their clinical implications.Front Neurol2024https://conductscience.org/library/papers/38938785PubMed
38664605Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study.J Headache Pain2024https://conductscience.org/library/papers/38664605PubMed
38637754An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity.J Headache Pain2024https://conductscience.org/library/papers/38637754PubMed
38549121Structural equation modeling for identifying the drivers of health-related quality of life improvement experienced by patients with migraine receiving eptinezumab.J Headache Pain2024https://conductscience.org/library/papers/38549121PubMed
38523607Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review.Front Neurol2024https://conductscience.org/library/papers/38523607PubMed
38405041Improvement of comorbid anxiety and depression in patients with migraine treated with injectable preventive calcitonin gene-related peptide antagonists: Review of clinical evidence.Saudi Pharm J2024https://conductscience.org/library/papers/38405041PubMed
38308209Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study.J Headache Pain2024https://conductscience.org/library/papers/38308209PubMed
38236314Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study.Neurol Ther2024https://conductscience.org/library/papers/38236314PubMed

See all 45 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CALCA796PubTator's text mininghttps://conductscience.org/library/genes/796

Source NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
EPTINEZUMABCHEMBL3833320Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3833320

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33740902

GET https://conductscience.org/api/papers/v1/33740902/references?page=2